| Project/Area Number |
25462335
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OZAKI TOSHIFUMI 岡山大学, 医歯(薬)学総合研究科, 教授 (40294459)
MATSUKAWA AKIHIRO 岡山大学, 医歯(薬)学総合研究科, 教授 (90264283)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | リン酸化プルラン / 転移性腫瘍 / 転移性骨腫瘍 / バイオテクノロジー |
|---|
| Outline of Final Research Achievements |
We investigated the availability of phosphorylated pullulan using with the therapeutic agents of bone malignant tumor. Breast cancer cell line (MDA-MB231), which is high frequency as the primary focus of metastatic bone tumor, was injected into the bone hole that was created by using a 24G needle to the central condylar of the nude mouse femur.These are divided into four groups, non-treatment group, the anti-cancer agent alone group, the anti-cancer agent + phosphorylated pullulan group, and phosphorylated pullulan group. We evaluated the antitumor effect using IVIS successively. Anti-cancer agent was using docetaxel. The antitumor effect was observed in the anti-cancer agent alone group and the anti-cancer agent + phosphorylated pullulan group. This result showed that the phosphorylated pullulan was suggested to be useful as a containing cement of anticancer agent.
|
